EICHORPublic-registry site landscape for NCT05579327, “Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)”, a Monocarboxylate Transporter 8 Deficiency study sponsored by Rare Thyroid Therapeutics International AB. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05579327 (registry record) |
| Study title | Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency) |
| Official title | Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Double-blind, Randomized, Placebo-controlled Study |
| Sponsor | Rare Thyroid Therapeutics International AB |
| Condition(s) | Monocarboxylate Transporter 8 Deficiency; Allan-Herndon-Dudley Syndrome |
| Phase | PHASE3 |
| Listed sites | 8 |
| Intervention(s) | Tiratricol, Placebo |
| Site countries | United States, Netherlands, United Kingdom |
Patient-friendly overview of this study: eichor.com/study/NCT05579327.
Eichor generates a preliminary site-risk snapshot for NCT05579327 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
